학술논문

A phase I, randomized, ascending-dose study to assess safety, pharmacokinetics, and activity of GDC-8264, a RIP1 inhibitor, in healthy volunteers
Document Type
Article
Source
In: Clinical and Translational Science. (Clinical and Translational Science, October 2023, 16(10):1997-2009)
Subject
Language
English
ISSN
17528062
17528054